Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the clinical case for DT120 as the company prepares for an FDA submission.
Definium Therapeutics has reported positive results from a second Phase 3 trial of DT120, a pharmaceutical formulation of lysergide, better known as LSD, in patients with generalized anxiety disorder (GAD).
The Panorama study is the second successful Phase 3 trial of DT120 in GAD and the company’s third positive Phase 3 readout for the drug overall, following earlier results in anxiety and major depressive disorder.
The result moves DT120 another step towards the conventional pharmaceutical regulatory pathway. Definium is planning a pre-New Drug Application (NDA) meeting with the US Food and Drug Administration in the fourth quarter of 2026 and currently expects to submit an NDA during the first half of 2027.
That does not make approval a certainty. The FDA will still need to assess the full clinical, safety and manufacturing package before making a regulatory decision. But with two successful Phase 3 trials in GAD, the programme now has a substantially larger late-stage evidence base than it did following its first pivotal result.
Second Phase 3 trial confirms anxiety signal
Panorama enrolled adults with generalized anxiety disorder and evaluated DT120 as a single-dose treatment.
Patients receiving the 100-microgram dose recorded a least-squares mean reduction of 9.8 points on the Hamilton Anxiety Rating Scale (HAM-A) after 12 weeks, compared with a 4.7-point reduction among patients receiving placebo.
The resulting placebo-adjusted difference was 5.1 points, with a p-value below 0.0001 and a standardised effect size of 0.64.
The effect also emerged quickly. Definium reported statistically significant differences in anxiety symptoms as early as Day 2, with the treatment effect maintained across the subsequent assessment points.
The study also met its key secondary endpoints, including measures of overall illness severity and anxiety symptoms at earlier timepoints.
At Week 12, 32% of patients in the 100-microgram group achieved at least a 50% reduction in HAM-A scores, compared with 14% of those receiving placebo. Fifteen per cent of patients receiving DT120 reached the study’s HAM-A remission threshold, compared with 4% in the placebo group.
The company reported that DT120 was generally well tolerated, with a safety profile consistent with previous clinical experience.
The results broadly reinforce the findings from Voyage, Definium’s earlier Phase 3 GAD study, which also produced a statistically significant placebo-adjusted reduction in anxiety symptoms.
That replication is important for a psychedelic programme because the design of these studies presents an unusual challenge: maintaining the integrity of the placebo comparison when participants may be able to recognise that they have received a psychoactive drug.
Tackling the blinding problem
Functional unblinding has become one of the recurring methodological questions in psychedelic drug development.
In a conventional pharmaceutical trial, participants generally should not know whether they have received the investigational medicine or placebo. With a psychedelic, the subjective effects can make that distinction considerably harder to maintain.
Panorama was designed in part to address that issue.
Alongside the 100-microgram dose and placebo groups, the study included a lower 50-microgram dose. The lower-dose group was intended to provide an additional active comparison rather than relying solely on an inactive placebo.
The approach gives researchers another way to examine whether the magnitude of the therapeutic effect is simply associated with participants recognising that they received a psychedelic, or whether the higher dose produces a distinct clinical effect.
Definium’s latest results therefore add another layer to the evidence supporting DT120, rather than simply reproducing the same trial design used in Voyage.
For psychedelic drug developers, that distinction matters as compounds move towards regulatory review. Demonstrating efficacy is only part of the challenge; companies must also convince regulators that the trial design can distinguish a pharmacological effect from expectations surrounding the psychedelic experience.
From LSD to a pharmaceutical product
DT120 is being developed as a pharmaceutical product rather than as a take-home psychedelic.
The treatment uses a defined dose of lysergide in an orally disintegrating tablet and is administered as a supervised intervention. The model is therefore substantially different from conventional daily psychiatric medication, but also different from the emerging commercial models built around psychedelic retreats or loosely structured psychedelic-assisted therapy.
That distinction is central to Definium’s development strategy.
The company is attempting to establish LSD within the conventional pharmaceutical framework: controlled manufacturing, defined dosing, clinical trial evidence, supervised administration and regulatory review.
If the programme eventually reaches approval, the significance would extend beyond the compound itself. It would provide another example of a classic psychedelic being developed as a regulated medicine through the same broad pharmaceutical pathway used for other psychiatric drugs.
Three Phase 3 wins
Panorama is now the third positive Phase 3 readout for DT120.
The first came in June, when Definium reported positive results from the Emerge Phase 3 study in major depressive disorder.
That was followed in August by positive results from Voyage, the first Phase 3 GAD study.
Panorama now provides a second late-stage dataset supporting DT120 in anxiety.
Taken together, the results give Definium a broader clinical package as it moves towards regulatory discussions with the FDA.
The company has indicated that it intends to discuss its NDA strategy with the agency during a pre-NDA meeting in the fourth quarter of 2026 before targeting a submission in the first half of 2027.
The eventual filing strategy, including which indication Definium seeks to pursue first, will be part of that regulatory process.
LSD is becoming a serious pharmaceutical development programme
The significance of DT120 extends beyond Definium’s individual clinical programme.
For decades, LSD has primarily been discussed in the context of recreational drug use, prohibition and psychedelic research. The development of a pharmaceutical formulation for a defined psychiatric indication represents a different proposition.
The goal is not to commercialise LSD as a general-purpose psychedelic experience.
It is to establish whether a precisely manufactured and dosed form of lysergide can produce a reproducible therapeutic effect under controlled clinical conditions.
The latest results suggest that question is increasingly being addressed through conventional drug development rather than exploratory psychedelic research.
That does not mean LSD has become an established treatment. DT120 still has to clear the regulatory process, and the clinical evidence will continue to face scrutiny around long-term safety, patient selection, dosing, administration and the practical delivery of psychedelic medicines.
But two positive Phase 3 GAD trials represent a materially different stage of development from the early clinical research that first brought psychedelics back into mainstream psychiatric research.
The FDA is now considering what psychedelic treatment could look like
The regulatory conversation is also developing alongside the clinical programmes.
On September 14, the FDA held a public hearing examining the potential future therapeutic use of psychedelic drugs in supervised and supportive settings.
The hearing addressed practical questions surrounding psychedelic medicines, including patient monitoring, provider training, data collection, safety and access.
Those questions are becoming increasingly relevant as companies such as Definium move towards potential commercialisation.
A psychedelic medicine cannot simply be approved and treated like a conventional tablet if its administration requires prolonged monitoring and specialised clinical oversight.
Healthcare providers will need to determine how patients are screened, where dosing takes place, who supervises the acute effects and how patients are monitored afterwards.
There are also questions around reimbursement, workforce training and the infrastructure required to deliver treatment at scale.
The FDA hearing demonstrates that these issues are no longer purely theoretical. They are becoming part of the regulatory discussion surrounding a potential future psychedelic medicine market.
What happens next for DT120?
Definium’s immediate priority is the regulatory process.
The company expects to meet with the FDA in the fourth quarter of 2026 to discuss its planned NDA before targeting a submission during the first half of 2027.
The agency will then have to assess the complete evidence package, including efficacy, safety and manufacturing data.
For now, the Panorama results provide another positive data point rather than a regulatory conclusion.
But the trajectory of DT120 is becoming increasingly clear.
The programme has now produced positive Phase 3 results in both generalized anxiety disorder and major depressive disorder, with GAD supported by two separate late-stage trials.
That puts Definium much closer to the point where the central question is no longer whether LSD can show a therapeutic signal in controlled research.
The next question is whether that evidence is sufficient to support an FDA-approved medicine, and whether healthcare systems can build a practical model for delivering it.
For psychedelic drug development, that represents a significant shift.
The industry is moving from proving that psychedelic compounds can have therapeutic effects towards proving that those effects can be translated into regulated, reproducible and scalable medicines.
DT120 is now one of the programmes at the centre of that transition.
